AstraZeneca prostate cancer drug fails in Phase III trial
AstraZeneca has suffered another setback in its late-stage R&D pipeline after its candidate prostate cancer drug zibotentan failed in a Phase III trial.
A 10mg daily oral dose of zibotentan failed to meet the primary endpoint of improved overall survival compared to standard care in the trial (Study 14), which included 594 patients with metastatic, castration-resistant prostate cancer.
Zibotentan is an endothelin A receptor blocker that had looked promising in earlier testing in prostate cancer, but based on the results AstraZeneca said it "plans no regulatory submissions for zibotentan at this time." The company said it was evaluating the results in further detail and would publish its findings in 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze